Altimmune, Inc. Sees Significant Premarket Surge Following Latest Update

Stock Performance Highlights

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Altimmune, Inc. (ALT) is seeing an impressive premarket surge today. The stock price has soared to $7.04, representing a significant 9.83% increase. This uptick comes with a trading volume of 89,573, indicating a surge in investor interest. The recent updates from Altimmune have grabbed the market’s attention, promising an exciting trading day ahead.

Positive News from Clinical Trials

The recent surge in Altimmune’s stock is attributed to positive news about the company’s progress in its clinical trials for ALT-801, a potential treatment for non-alcoholic steatohepatitis (NASH). These encouraging trial results have boosted investor confidence in Altimmune’s prospects, driving the premarket performance upwards. As the market responds to this optimistic development, all eyes will be on Altimmune to see how it continues to advance its growth trajectory.

Clinical Trial Details

The trial enrolled 391 subjects with obesity, or overweight with at least one co-morbidity and without diabetes. Subjects were randomized 1:1:1:1 to receive 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or a placebo administered weekly for 48 weeks in conjunction with diet and exercise. A subgroup of subjects was evaluated in a body composition analysis.

At Week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively, with a near-linear continued weight loss observed on the 2.4 mg dose at the end of treatment. The full MRI-based body composition analysis included 50 subjects who received pemvidutide and showed that subjects in the pemvidutide groups had an average lean mass loss of 21.9%, with 78.1% of weight loss attributable to fat. Additionally, pemvidutide resulted in robust reductions in serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias, or clinically meaningful increases in heart rate.

Looking Ahead

Given the promising results from its clinical trials, Altimmune appears to have a bright future. Investors will likely keep a close watch on the company’s next moves and further progress in their trials. This recent spike in stock price showcases the market’s confidence in Altimmune’s capability to deliver effective treatments and achieve substantial growth in the biotechnology sector.